General vaccination with a combined measles, mumps, and rubella vaccine was introduced in Sweden in 1982.
Introduction
In 1982 a new strategy for immunisation against measles, mumps, and rubella was introduced in Sweden, which was expected to give more complete protection at all ages within relatively few years.' The vaccination schedule includes two injections of the combined vaccine, given at 18 months and 12 years of age. Vaccinating at 18 months only was abandoned because of the risk of increasing numbers of people remaining unprotected among those left unvaccinated or who had failed to seroconvert after the first injection.2 It was also feared that as younger, already vaccinated and predominantly immune age groups stopped being the usual source of infection older, unvaccinated children and adolescents would no longer be exposed to the natural wild infections. The ultimate aim of the new strategy is rapid elimination of all three diseases. To assess the rate of seroconversion and the occurrence of clinical reactions after injection of the commercially available combined vaccine we carried out a controlled trial in 150 children aged 18 months. Clinical reactions after vaccination of schoolchildren were assessed over a longer period but less rigorously. 3 (02",,) . Mumps symptoms were seen in one, and neck lymphadenitis combined with fever and rash in two. In another school a group of 128 vaccinated children returned a form for daily recording of signs and symptoms occurring within 28 days after immunisation. Three of the children (23 -3) reported arthralgia, fever was notified by 9 (7 0', ,), and cervical lymphadenitis by one.
Material and methods
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Comment As in other countries, public opinion in Sweden is extremely sensitive to reports of major side effects of drugs and vaccines. Hence to secure a vaccine acceptance rate high enough to ensure the eventual elimination of measles, mumps, and rubella it was considered necessary to supply a valid estimate of the average incidence and clinical severity of the adverse reactions expected with the combined immunisation programme, especially among the youngest target group.
To enable us to compare the incidence of vaccine reactions reported during this trial with earlier experiences of the same vaccine in the United States we arranged our clinical findings according to an arbitrarily chosen time scheme closely similar to that used in a representative American study9-namely, by subdividing the total four week observation period into three unequal intervals of 0-4, 5-12, and 13-28 days after vaccine administration (table 1) .
In both studies most of the clinical symptoms (notified predominantly between days 5 and 12) were mild and lasted only a few days. Even during periods of high fever (>r395°C)-found in about one fifth of the children-most of the children did not appear particularly sick or fretful and apparently behaved more or less normally.
The lack of a comparable control group precluded an exact evaluation of the true vaccine reaction rates, but the observed clustering of recorded clinical complaints five to 12 days after immunisation (table I) suggests that these were caused by the vaccine. The few fevers and rashes notified more than two weeks after vaccination probably reflect the expected patterns observed in children of that age.
The preliminary results in schoolchildren showed that fevers or other reactions were few and mild. The recorded incidences and severity of fever, rash, and arthralgia in the immunised 12 year old children were no higher than would normally be expected during any month in a school population of that age. Notwithstanding the difficulty of comparing the rates of side effects in the 18 month old children with those in the 12 year olds, the results do suggest that there may be an age difference in vaccine reactions. The apparently higher incidence of fever and other complaints at 18 months than at 12 years may to some extent have been due to the fact that most of the 12 year old children had experienced some of the diseases already; nevertheless, that cannot be the only explanation.
The difference in incidences of high fever and rash produced by the two vaccine batches used in this study was further investigated by continued recording of these symptoms at the same well baby clinics during several months after the start of the general immunisation programme, which used two further commer,cial batches of the combined vaccine (table II).
The average incidence of high fever produced by vaccines C and D (pooled incidence 15%") was also significantly lower than that found for vaccine B (p < 001). The overall incidence of high fever calculated for the total series of 279 children (52 cases; 190/) was considered to be the best available estimate of the incidence of high fever expected to occur as a side effect of vaccination in Swedish children aged 18 months.
Preliminary experience with the general child immunisation programme based on mandatory notifications to the Swedish Adverse Drug Reaction Committee of serious or unexpected side effects showed an almost negligible incidence of such reactions. The few that did occur bore no relation to the important complications of the three diseases that the mass vaccination campaign aims at preventing.
The satisfactory seroconversion rates (see figure) support the feasibility of complete eradication of the three diseases. The two step vaccination programme vas chosen to avoid having a generation of young susceptible adults who have escaped natural exposure to the three viruses by virtue of the young vaccinees no longer being the usual source of infection. Such a development recently occurred in the United States. Outbreaks of measles"' among university and college students occurred in 1982 and 1983, more than half of all the reported measles cases emanating from this group; over 20 000 students had to be vaccinated.
Of the few children who fail to seroconvert or escape immunisation at 18 months, most may-even after the elimination of natural infection-be expected to be vaccinated with a positive result at the second stage of the Swedish vaccination programme at the age of 12.
(Accepted 10 May 1983) MEDICINES RESISTING POISON-Such medicines are called Alexiteria, and Alexipharmaca, which resist poison. Some of these resist poison by astral influence, and some physicians (though but few) can give a reason for it. These they have sorted into three ranks: 1. Such as strengthen nature, that so it may tame the poison the easier. 2. Such as oppose the poison by a contrary quality. 3. Such as violently thrust it out of doors. Such as strengthen nature against poison, either do it to the body universally, or else strengthen some particular part thereof. For many times one particular part of the body is most afflicted by the poison, suppose the stomach, liver, brain, or any other part: such as cherish and strengthen those parts, being weakened, may be said to resist poison. Such as strengthen the spirits, strengthen all the body. Sometimes poisons kill by their quality, and then are they to be corrected by their contraries. They which kill by cooling are to be remedied by heating, and the contrary; they which kill by corroding, are to be cured by lenitives, such as temper their acrimony. Those which kill by induration, or coagulation, require cutting medicines. Also because all poisons are in motion, neither stay they in one till they have seized and oppressed the fountain of life, therefore they have invented another faculty to stay their motion, viz terrene and emplastic. For they judge, if the poison light upon these medicines, they embrace them round with a viscous quality. Also they say the ways and passages are stopped by such means, to hinder their proceeding; take Terra Lemnia for one. Truly if these reasons be good, which I leave to future time to determine, it may be done for little cost. Some are of opinion that the safest way is to expel the poison out of the body, so soon as may be, and that is done by vomit, or purge, or sweat. You need not question the time, but do it as soon as may be; for there is no parlying with poison. Let vomiting be the first, purging the next, and sweating the last. This is general. But, If thou dost but observe the nature and motion of the venom, that will be thy best instructor. In the stomach it requires vomiting, in the blood and spirits, sweating, if the body be plethoric, bleeding, if full of evil humours, purging. Lastly, The cure being ended, strengthen the parts afflicted. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
